22157.jpg
2 Day Virtual Variations to Marketing Authorisations Training Course
31 janv. 2024 04h47 HE | Research and Markets
Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "Variations to Marketing Authorisations Training Course" conference has been added to ResearchAndMarkets.com's offering. It is a key post-marketing...
Company logo.png
Pharmazz, Inc. Announces Marketing Approval of Sovateltide in India for Acute Cerebral Ischemic Stroke Patients
31 mai 2023 09h19 HE | Pharmazz, Inc.
The proportion of acute cerebral ischemic stroke patients with the mRS of 0-2 on day 90 post-randomization was statistically significant (p=0.002) Sovateltide is a first-in-class drug that...
22157.jpg
Variations to Marketing Authorisations Training Course: Optimising Regulatory Procedures to Achieve Faster Approval
02 mai 2023 08h03 HE | Research and Markets
Dublin, May 02, 2023 (GLOBE NEWSWIRE) -- The "Variations to Marketing Authorisations Training Course" conference has been added to ResearchAndMarkets.com's offering. It is a key post-marketing...
July 30, 2021 - ROSEN LOGO.jpg
OWLT LOSS ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Owlet, Inc. Investors with Losses to Secure Counsel Before Important January 18 Deadline in Securities Class Action – OWLT
28 déc. 2021 18h15 HE | The Rosen Law Firm PA
NEW YORK, Dec. 28, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds: (a) purchasers of the securities of Owlet, Inc. (NYSE: OWLT) between March 31, 2021 and...
22157.jpg
Global Orphan Drugs Market Report 2021-2026 Featuring Market Leaders - AbbVie, Eli Lilly, Johnson & Johnson, Merck & Co., Pfizer and Sanofi-Aventis
06 août 2021 04h53 HE | Research and Markets
Dublin, Aug. 06, 2021 (GLOBE NEWSWIRE) -- The "Global Markets for Orphan Drugs" report has been added to ResearchAndMarkets.com's offering. The Global Orphan Drug Market is Set to Grow to $191...
22157.jpg
Global Rare Diseases Drug Development, Clinical Trials and the Regulatory Landscape Report 2021 with Analysis of Trends and Characteristics of Clinical Trials from 1999-2018
12 janv. 2021 09h28 HE | Research and Markets
Dublin, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The "Drug Development in Rare Diseases: Focus on Clinical Trials and the Regulatory Landscape" report has been added to ResearchAndMarkets.com's offering....
20170406 Telix Logo.png
Telix Pharmaceuticals submits European marketing authorisation application for prostate cancer imaging product
30 avr. 2020 20h14 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE, Belgium, May 01, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that it has submitted a marketing...
INNATEvertnoir.png
The European Medicines Agency Accepts the Regulatory Submission for Lumoxiti in Relapsed or Refractory Hairy Cell Leukemia
02 janv. 2020 01h00 HE | INNATE PHARMA
MARSEILLE, France, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the European Medicines...
IGX Logo Medium Size.jpg
The Spanish Agency of Medicines and Medical Devices Grants Marketing Authorization of RIZAPORT®
31 oct. 2018 08h00 HE | IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Oct. 31, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) is pleased to announced that its commercialization partner for...